SIGA Technologies reported a net loss for the fourth quarter of 2025 due to significantly lower product sales compared to the prior year period. Despite the quarterly loss, the company remained profitable for the full fiscal year and secured substantial new government funding for development programs.

SIGA Technologies reported total revenues of $7.0 million for the first quarter of 2025, a significant decrease from $25.4 million in the same period last year. The company experienced a net loss of $0.4 million, or $0.01 per diluted share, compared to a net income of $10.3 million, or $0.14 per diluted share, in Q1 2024. Despite the decline in sales, SIGA highlighted steady progress on key initiatives and anticipated substantial sales in the coming months from outstanding orders.

SIGA Technologies saw a drop in revenue and net income in Q4 2024 compared to the same period in 2023. Product sales decreased significantly, impacting total revenue. The company continues to rely on government procurement orders, with notable contributions from the U.S. Strategic National Stockpile and international sales.

SIGA Technologies reported a profitable third quarter, driven by a $122 million in procurement orders, including a major order for oral TPOXX. The company is positioned for substantial revenue in Q4 2024 and 2025, with $146 million in outstanding orders.

SIGA Technologies reported a strong second quarter in 2024, with total revenues of $21.8 million, driven by product sales of $20.7 million. The company achieved a net income of $1.8 million, resulting in a diluted income per share of $0.03. Additionally, SIGA received a $113 million procurement order from the U.S. Government for oral TPOXX in July.

SIGA Technologies reported a successful first quarter with product revenues reaching $24 million and pre-tax operating income of $11 million, both showing an increase compared to the same quarter in the previous year. The company remains focused on advancing its strategy, progressing clinical programs, and negotiating the next contract with the U.S. Government.

SIGA Technologies reported strong financial results for Q4 2023, with significant increases in product sales and pre-tax operating income compared to the same period in 2022. The company's performance highlights the strength and growth potential of its business model within the public health sector.

SIGA Technologies reported a significant decrease in revenue for the third quarter of 2023, moving from $72.2 million in 2022 to $9.2 million. This resulted in a net loss of $0.4 million, a stark contrast to the $33.0 million net income reported in the same quarter of the previous year. The diluted loss per share was $0.01, compared to a diluted income per share of $0.45 in Q3 2022.

SIGA Technologies reported a decrease in total revenues and a loss in net income for Q2 2023 compared to Q2 2022. However, the company anticipates a significant increase in revenues during the second half of the year, driven by recent U.S. government orders for oral and IV TPOXX, and expects to achieve full-year 2023 pre-tax operating income between $90 million and $100 million.

SIGA Technologies reported a decrease in total revenues to $8.3 million for the three months ended March 31, 2023, compared to $10.5 million for the same period in 2022. The company experienced a net loss of $0.9 million, with a diluted loss per share of $0.01. Despite the overall loss, SIGA is targeting significant oral TPOXX deliveries to the DoD and SNS throughout 2023.

SIGA Technologies reported a decrease in total revenues to $11.4 million and an operating loss of $1.8 million for the three months ended December 31, 2022. Net loss for the quarter was $0.8 million, with a diluted loss per share of $0.01. The company had approximately $111 million in revenue in 2022, including approximately $71 million of international sales.

SIGA Technologies reported strong Q3 2022 financial results, driven by significant international sales of oral TPOXX and diversification of its revenue base with new customers and product formulations. Total revenue reached $72.2 million, with a net income of $33.0 million and diluted earnings per share of $0.45.

SIGA Technologies reported a strong second quarter in 2022, marked by increased revenues driven by initial sales of oral TPOXX to the Asia-Pacific region and the U.S. Department of Defense, alongside ongoing international orders.

SIGA Technologies reported a revenue increase for the three months ended March 31, 2022, driven by the first sale of intravenous TPOXX to the U.S. government and a new international contract. The company also declared a special dividend of $0.45 per share.

SIGA Technologies reported a substantial increase in revenue and net income for the fourth quarter of 2021, primarily due to increased product sales of oral TPOXX to the U.S. government. The company's strategic focus on health security and successful partnerships have contributed to its financial success.

SIGA Technologies reported a challenging third quarter with a net loss of $3.1 million and total revenues of $4.8 million, a significant decrease from the $44.3 million in revenue and $24.2 million net income reported in the same period last year. However, the company anticipates delivering up to $113 million of oral TPOXX to the U.S. government in the fourth quarter. The company also repurchased 1.1 million shares for $7.1 million during the quarter.

SIGA Technologies reported Q2 2021 financial results with a decrease in total revenues to $8.7 million compared to $40.3 million in Q2 2020. Net income decreased to $0.2 million from $20.9 million in the same period last year. However, the company saw $7 million in international revenues from oral TPOXX® deliveries to Canada.

SIGA Technologies reported a positive trend in international sales, with approximately $3 million of oral TPOXX® delivered to the Public Health Agency of Canada in the first quarter. Total revenues increased to $4.8 million compared to $2.6 million in the same period last year. The company's operating loss was $(2.0) million, and its net loss was $(0.8) million, with a diluted loss per share of $(0.02).

SIGA Technologies reported financial results for the three and twelve months ended December 31, 2020. The fourth quarter was highlighted by the delivery of approximately 112,000 courses of oral TPOXX® to the U.S. strategic national stockpile (SNS), generating revenue of approximately $35 million. The company also announced the first international contract for oral TPOXX® with the contract award by the Canadian Military for its procurement.

SIGA Technologies reported a substantial increase in revenue and net income for the third quarter of 2020. The company's performance was driven by the delivery of approximately 134,000 courses of oral TPOXX® to the Strategic National Stockpile (SNS). SIGA has also seen growth in their international business, with the Public Health Agency of Canada announcing their intent to purchase up to 33,300 courses of oral TPOXX®.

SIGA Technologies reported strong financial results for the second quarter of 2020, with total revenues of $40.3 million compared to $3.9 million in the same period of 2019. The company achieved a net income of $20.9 million, a significant increase from the net loss of $3.2 million in the second quarter of the previous year. This quarter was marked by initial deliveries of TPOXX® to the U.S. Strategic National Stockpile and the Canadian Department of Defence.

SIGA Technologies reported a revenue of $2.6 million for the first quarter of 2020, resulting in an operating loss of $4.0 million. The company's loss per diluted share was $0.11, and cash and cash equivalents totaled $77.4 million. Recent activities include BARDA exercising procurement options for $101.3 million and the Canadian Department of National Defence awarding a contract for up to 15,325 courses of oral TPOXX® over four years.

SIGA Technologies reported a revenue of approximately $27 million and an operating loss of approximately $2 million for the year ended December 31, 2019. The company's cash and cash equivalents were approximately $161 million at the end of the year. SIGA also announced product delivery expectations for oral TPOXX® and a $50 million share repurchase program.